Atomoxetine, a Novel Treatment for Attention‐Deficit—Hyperactivity Disorder

  title={Atomoxetine, a Novel Treatment for Attention‐Deficit—Hyperactivity Disorder},
  author={Alisa K. Christman and Joli D. Fermo and John Seth Markowitz},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
Atomoxetine is the first nonstimulant drug approved by the United States Food and Drug Administration (FDA) for the treatment of attention‐deficit–hyperactivity disorder (ADHD), and the only agent approved by the FDA for the treatment of ADHD in adults. Atomoxetine is a norepinephrine transport inhibitor that acts almost exclusively on the noradrenergic pathway. Its mechanism of action in the control and maintenance of ADHD symptoms is thought to be through the highly specific presynaptic… 
Atomoxetine for individuals with traumatic brain injury.
  • D. Ripley
  • Medicine, Psychology
    The Journal of head trauma rehabilitation
  • 2006
Unlike most medications used to treat attentional disorders, atomoxetine is not a Drug Enforcement Agency Schedule II medication and, therefore, is more convenient for physicians and patients, as unique prescriptions are not needed for each month’s dosage, and onceor twicedaily dosing can potentially eliminate the need for dosing during school or work hours.
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder
This review focuses on the tolerability, occurrence of adverse events, precautions required to prevent severe adverse Events, and essential pharmacological interaction in the treatment of ADHD symptoms by non-stimulants.
Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder
  • R. Weisler
  • Medicine, Psychology
    Expert opinion on pharmacotherapy
  • 2007
A number of long-acting medications for the treatment of attention deficit hyperactivity disorder (ADHD) have recently been developed and approved for use in the US and appear to have a lower risk of abuse and diversion and may be associated with significant improvements in medication adherence.
Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder
Current evidence suggests that, for the majority of those treated for ADHD, the medications currently available pose little in the way of risk of significant harm, and potential but unlikely long-term treatment effects need to be investigated as carefully as possible.
Stimulants and Other Non-stimulants for Attention-Deficit/Hyperactivity Disorder (ADHD)
The pharmacodynamic benefits and adverse effects of methylphenidate, amphetamines, and atomoxetine may be linked to their pharmacokinetic profiles.
Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation
  • A. Ornoy
  • Psychology, Medicine
    Pharmaceutical Research
  • 2017
The drugs used for the treatment of ADHD are apparently not teratogenic, but due to paucity of data, especially on the long-term neurodevelopmental outcome, the treating physician should reconsider the need of treatment during pregnancy.
tomoxetine Improved Response Inhibition in Adults ith Attention Deficit/Hyperactivity Disorder
The selective noradrenaline reuptake inhibitor atomxetine shows efficacy in the treatment of ADHD and epresents the only licensed nonstimulant pharmacologic treatent currently available for the disorder.
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.
The pharmacokinetics of atomoxetine in extensive metabolizer patients were well characterized over a wide range of doses in this study and were similar after adjustment for body weight.


Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Cardiac effects and effects on weight, height, and metabolism that are related to treatment of ADHD with atomoxetine in children and adolescents are discussed.
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms.
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Two studies early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD and was found to be well tolerated.
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
Atomoxetine was found to be effective and well tolerated for the treatment of ADHD in school-age girls and superior to placebo on the following measures.
Novel treatments for attention-deficit/hyperactivity disorder in children.
Atomoxetine, which is being developed for ADHD, reduces symptoms of ADHD without exacerbating comorbid conditions and is associated with only minor side effects, including subtle changes in blood pressure and heart rate.
Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study
Once-daily administration of atomoxetine is an effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD) as assessed by investigator, parent, and teacher ratings.
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated, and these promising results provide support for further studies of tomoxettine over an extended period of treatment.
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adults, while further validating the continuity of pharmacological responsivity of ADHD across the lifespan.